Yongkang Xu

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Metastatic Colorectal Cancer

Clinical Practice

Top Venues

Cancer medicine

Cancer management and research

OncoTargets and therapy

Therapeutics and clinical risk management

This page only lists publications with an associated author ORCID identifier.

Publications

Shumin Fu, Yongkang Xu, Ye Mao, Mengting He, Zhimeng Chen, Shenglan Huang, Dan Li, Yaqin Lv, Jianbing Wu
Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma. Cancer medicine 13 (9) (2024)
Zhengyi Wu, Liang Sun, Yongkang Xu, He Huang, Zhipeng Wu, Bingbing Qiu, Jinlong Yan, Xiangbao Yin
The Value of Chemokine and Chemokine Receptors in Diagnosis, Prognosis, and Immunotherapy of Hepatocellular Carcinoma. Cancer management and research 16 (2024)
Shumin Fu, Yongkang Xu, Ye Mao, Mengting He, Zhimeng Chen, Shenglan Huang, Dan Li, Yaqin Lv, Jianbing Wu
Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma. Cancer medicine 13 (9) (2024)
Zhengyi Wu, Liang Sun, Yongkang Xu, He Huang, Zhipeng Wu, Bingbing Qiu, Jinlong Yan, Xiangbao Yin
The Value of Chemokine and Chemokine Receptors in Diagnosis, Prognosis, and Immunotherapy of Hepatocellular Carcinoma. Cancer management and research 16 (2024)
Shumin Fu, Yongkang Xu, Ye Mao, Mengting He, Zhimeng Chen, Shenglan Huang, Dan Li, Yaqin Lv, Jianbing Wu
Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma. Cancer medicine 13 (9) (2024)
Yongkang Xu, Shumin Fu, Kan Liu, Ye Mao, Jianbing Wu
Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study. Therapeutics and clinical risk management 19 (2023)
Kan Liu, Jianbing Wu, Yongkang Xu, Dan Li, Shenlang Huang, Ye Mao
Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice. OncoTargets and therapy 15 (2022)